Clinical trial

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

NCT00297089

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-11-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2006-11-01Date precision: month

Registry last updated2013-01-31

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancerunresolved

NSCLCunresolved

Non-Small-Cell Lung Cancerunresolved

Interventions

ABT-751DRUG

pemetrexedDRUG · verified · RxNorm: pemetrexed

placeboDRUG

Sponsors & collaborators

AbbVie (prior sponsor, Abbott)lead sponsor

Mapped research locations

BaltimoreMaryland, United States2 PragueCzechia2 ThessalonikiGreece2 BrnoCzechia2 ChicagoIllinois, United States1 PhiladelphiaPennsylvania, United States1 St LouisMissouri, United States1 AtlantaGeorgia, United States1 ColumbusOhio, United States1 IndianapolisIndiana, United States1 BethesdaMaryland, United States1 BudapestHungary1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00297089 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.